Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasm Metastasis 1Hemangiosarcoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × Vascular Endothelial Growth Factor A × Clear all
NCT01551745 2021-10-19

Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab

Gradalis, Inc.

Phase 2 Completed
5 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01767792 2021-02-12

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

University of Alabama at Birmingham

Phase 2 Completed
22 enrolled 14 charts
CNS

Neurofibromatosis 2

NCT00483834 2019-02-15

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

University Health Network, Toronto

Phase 2 Completed
50 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00288015 2018-06-25

Bevacizumab in Treating Patients With Angiosarcoma

Northwestern University

Phase 2 Completed
32 enrolled 12 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡